# Comprehensive Perturbation Analysis Report

**Query:** Which one has teh most KO effect, is it Dimethyl fumarate or CHCHD2
**Date:** 2025-11-17 03:27:27

**Total Perturbations:** 2
**Successful:** 2
**Comparison:** ✓ Generated (76 shared pathways, 0 shared phenotypes)

---

## Perturbation 1: CHCHD2 (gene)

## Key Results

**Differential Expression:** 384 significantly differentially expressed genes (p ≤ 0.05) out of 1950 total genes

**Top Upregulated Genes:**
1. **DHRS4**: log2FC=1.19, p=7.003e-03, p_adj=1.000 (perturbed: 0.30, control: 0.13)
2. **GPAM**: log2FC=1.08, p=3.399e-03, p_adj=1.000 (perturbed: 0.44, control: 0.21)
3. **EPB41**: log2FC=1.07, p=4.380e-04, p_adj=0.854 (perturbed: 0.63, control: 0.30)
4. **MFSD4B**: log2FC=1.02, p=4.454e-03, p_adj=1.000 (perturbed: 0.46, control: 0.23)
5. **SCD**: log2FC=0.96, p=3.626e-04, p_adj=0.707 (perturbed: 0.81, control: 0.41)
6. **NUDT4**: log2FC=0.94, p=2.316e-05, p_adj=0.045 (perturbed: 1.11, control: 0.58)
7. **TRAPPC6B**: log2FC=0.92, p=2.501e-04, p_adj=0.488 (perturbed: 0.89, control: 0.47)
8. **GALNT10**: log2FC=0.92, p=2.351e-05, p_adj=0.046 (perturbed: 1.18, control: 0.63)
9. **GK5**: log2FC=0.89, p=2.287e-03, p_adj=1.000 (perturbed: 0.68, control: 0.37)
10. **ERCC6**: log2FC=0.88, p=1.101e-02, p_adj=1.000 (perturbed: 0.49, control: 0.27)

**Top Downregulated Genes:**
1. **CYCS**: log2FC=-0.05, p=4.100e-02, p_adj=1.000 (perturbed: 5.88, control: 6.09)
2. **RAB5IF**: log2FC=-0.05, p=1.488e-02, p_adj=1.000 (perturbed: 5.91, control: 6.14)
3. **CEBPB**: log2FC=-0.08, p=2.343e-03, p_adj=1.000 (perturbed: 5.71, control: 6.05)
4. **LAPTM4A**: log2FC=-0.11, p=4.750e-02, p_adj=1.000 (perturbed: 4.29, control: 4.62)
5. **MT2A**: log2FC=-0.13, p=4.350e-06, p_adj=0.008 (perturbed: 6.51, control: 7.11)
6. **NEAT1**: log2FC=-0.13, p=8.968e-03, p_adj=1.000 (perturbed: 4.67, control: 5.12)
7. **GSTO1**: log2FC=-0.13, p=7.313e-03, p_adj=1.000 (perturbed: 4.50, control: 4.94)
8. **CTSD**: log2FC=-0.14, p=3.723e-02, p_adj=1.000 (perturbed: 4.07, control: 4.47)
9. **HLA-C**: log2FC=-0.15, p=7.583e-13, p_adj=0.000 (perturbed: 5.92, control: 6.58)
10. **SLC20A1**: log2FC=-0.17, p=3.203e-02, p_adj=1.000 (perturbed: 3.52, control: 3.95)


![Volcano Plot](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/volcano.png)

**Pathway Enrichment:** 8 significantly enriched pathways (p ≤ 0.05)

Top enriched pathways:
1. Phospholipase D signaling pathway (NES=1.59, p=2.222e-02, FDR=0.332)
2. Sphingolipid signaling pathway (NES=1.59, p=1.667e-02, FDR=0.273)
3. Thyroid hormone signaling pathway (NES=1.59, p=1.613e-02, FDR=0.229)
4. Fanconi anemia pathway (NES=1.58, p=1.754e-02, FDR=0.225)
5. Insulin signaling pathway (NES=1.56, p=3.509e-02, FDR=0.229)
6. Chronic myeloid leukemia (NES=1.55, p=3.509e-02, FDR=0.174)
7. Adrenergic signaling in cardiomyocytes (NES=1.45, p=4.615e-02, FDR=0.309)
8. Small cell lung cancer (NES=1.41, p=3.846e-02, FDR=0.292)

![Pathway Enrichment](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/pathway_enrichment.png)


![RNA GSEA Enrichment Plot](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/rna_gsea.png)

## Mechanistic Hypotheses

No hypotheses generated.

## Limitations & Notes

- **Computational Predictions:** This analysis is based on computational predictions and requires experimental validation.
- **Literature Evidence:** Literature support classification is automated and should be manually reviewed for critical hypotheses.
- **Tissue/Cell Context:** Results are specific to the analyzed cell type and may not generalize to other contexts.
- **Dynamic Processes:** This analysis represents a snapshot and does not capture temporal dynamics of cellular responses.

---

*Report generated by Virtual Cell system*


---

## Perturbation 2: [('Dimethyl fumarate', 5.0, 'uM')] (drug)

## Key Results

**Pathway Enrichment:** 3 significantly enriched pathways (p ≤ 0.05)

Top enriched pathways:
1. Wnt signaling pathway (NES=-1.66, p=1.111e-02, FDR=1.000)
2. Signaling pathways regulating pluripotency of stem cells (NES=-1.53, p=2.299e-02, FDR=1.000)
3. Huntington disease (NES=1.29, p=5.000e-02, FDR=0.861)

![Pathway Enrichment](/home/nebius/cellian/llm/perturbation_outputs/drug_[__Dimethyl fumarate_, 5.0, _uM__]/pathway_enrichment.png)

## Mechanistic Hypotheses

No hypotheses generated.

## Limitations & Notes

- **Computational Predictions:** This analysis is based on computational predictions and requires experimental validation.
- **Literature Evidence:** Literature support classification is automated and should be manually reviewed for critical hypotheses.
- **Tissue/Cell Context:** Results are specific to the analyzed cell type and may not generalize to other contexts.
- **Dynamic Processes:** This analysis represents a snapshot and does not capture temporal dynamics of cellular responses.

---

*Report generated by Virtual Cell system*


---

## Comparison Analysis

**Comparison:** Perturbation 1 vs Perturbation 2

### Shared Pathways (76)

- **Platelet activation**: Perturbation 1 NES=1.07, Perturbation 2 NES=-1.13 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Transcriptional misregulation in cancer**: Perturbation 1 NES=-0.70, Perturbation 2 NES=-1.16 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Toxoplasmosis**: Perturbation 1 NES=-0.70, Perturbation 2 NES=-1.17 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Cellular senescence**: Perturbation 1 NES=1.05, Perturbation 2 NES=-1.32 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Amyotrophic lateral sclerosis**: Perturbation 1 NES=-0.79, Perturbation 2 NES=0.96 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Pathogenic Escherichia coli infection**: Perturbation 1 NES=0.87, Perturbation 2 NES=0.88 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Axon guidance**: Perturbation 1 NES=1.26, Perturbation 2 NES=-1.05 (stronger: CHCHD2)
- **Prion disease**: Perturbation 1 NES=1.14, Perturbation 2 NES=-0.82 (stronger: CHCHD2)
- **Wnt signaling pathway**: Perturbation 1 NES=1.28, Perturbation 2 NES=-1.66 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Human immunodeficiency virus 1 infection**: Perturbation 1 NES=0.77, Perturbation 2 NES=-1.26 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Chemokine signaling pathway**: Perturbation 1 NES=1.11, Perturbation 2 NES=-0.67 (stronger: CHCHD2)
- **Salmonella infection**: Perturbation 1 NES=0.85, Perturbation 2 NES=-1.07 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Chemical carcinogenesis**: Perturbation 1 NES=0.73, Perturbation 2 NES=-1.24 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **cGMP-PKG signaling pathway**: Perturbation 1 NES=1.18, Perturbation 2 NES=-1.05 (stronger: CHCHD2)
- **MicroRNAs in cancer**: Perturbation 1 NES=1.18, Perturbation 2 NES=-0.99 (stronger: CHCHD2)
- **Proteoglycans in cancer**: Perturbation 1 NES=1.35, Perturbation 2 NES=-0.91 (stronger: CHCHD2)
- **Prostate cancer**: Perturbation 1 NES=1.40, Perturbation 2 NES=-0.77 (stronger: CHCHD2)
- **PI3K-Akt signaling pathway**: Perturbation 1 NES=1.01, Perturbation 2 NES=-0.62 (stronger: CHCHD2)
- **Phagosome**: Perturbation 1 NES=-0.75, Perturbation 2 NES=-0.75 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Signaling pathways regulating pluripotency of stem cells**: Perturbation 1 NES=1.09, Perturbation 2 NES=-1.53 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])

No shared phenotypes found.

### Summary

## Comparison Summary

**Comparison: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')]**

### Pathway Effects

- **Platelet activation**: CHCHD2 activation (NES 1.07), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.13)
- **Transcriptional misregulation in cancer**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.70 vs -1.16)
- **Toxoplasmosis**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.70 vs -1.17)
- **Cellular senescence**: CHCHD2 activation (NES 1.05), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.32)
- **Amyotrophic lateral sclerosis**: CHCHD2 repression (NES -0.79), [('Dimethyl fumarate', 5.0, 'uM')] activation (NES 0.96)
- **Pathogenic Escherichia coli infection**: Both activation, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES 0.87 vs 0.88)
- **Axon guidance**: CHCHD2 activation (NES 1.26), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.05)
- **Prion disease**: CHCHD2 activation (NES 1.14), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.82)
- **Wnt signaling pathway**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.66)
- **Human immunodeficiency virus 1 infection**: CHCHD2 activation (NES 0.77), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.26)

## Mechanistic Hypotheses

Generated 4 testable mechanistic hypotheses:

### Hypothesis H1: "statement": "CHCHD2 perturbation leads to a stronger downregulation of Wnt signaling compared to Dimethyl fumarate treatment.",

**Literature Support:** WEAK
Weak or indirect evidence. Found 3 potentially relevant papers but limited direct support.
**Supporting Papers:**
- Placeholder result 1 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation leads stronger
- Placeholder result 2 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation leads stronger
- Placeholder result 3 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation leads stronger

---

### Hypothesis H2: "statement": "Dimethyl fumarate has a greater impact on the Phospholipase D signaling pathway than CHCHD2 perturbation.",

**Literature Support:** WEAK
Weak or indirect evidence. Found 3 potentially relevant papers but limited direct support.
**Supporting Papers:**
- Placeholder result 1 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] fumarate greater impact
- Placeholder result 2 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] fumarate greater impact
- Placeholder result 3 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] fumarate greater impact

---

### Hypothesis H3: "statement": "CHCHD2 perturbation has a stronger negative regulatory effect on genes TM7SF2, BSCL2, ACY1, and ARHGEF18, leading to their downregulation, whereas Dimethyl fumarate's impact on these genes is less pronounced.",

**Literature Support:** WEAK
Weak or indirect evidence. Found 3 potentially relevant papers but limited direct support.
**Supporting Papers:**
- Placeholder result 1 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation stronger negative
- Placeholder result 2 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation stronger negative
- Placeholder result 3 for query: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')] perturbation stronger negative

---

### Hypothesis H4: "statement": "Dimethyl fumarate treatment has a more substantial influence on the activation of the Insulin signaling pathway relative to CHCHD2 perturbation.",

**Literature Support:** WEAK
Weak or indirect evidence. Found 3 potentially relevant papers but limited direct support.
**Supporting Papers:**
- Placeholder result 1 for query: 
- Placeholder result 2 for query: 
- Placeholder result 3 for query: 

---

---

*Comprehensive report generated by Virtual Cell system*
